Tenaya Therapeutics/TNYA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Tenaya Therapeutics

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Ticker

TNYA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

South san francisco, United States

Employees

140

TNYA Metrics

BasicAdvanced
$331M
Market cap
-
P/E ratio
-$1.65
EPS
-
Beta
-
Dividend rate
$331M
$8.09
$1.66
8.6
6.718
-57.91%
-66.69%
-63.59%
2.09
2.09
33.27%

What the Analysts think about TNYA

Analyst Ratings

Majority rating from 8 analysts.
Buy

TNYA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$32M
7.69%
Profit margin
0.00%
NaN%

TNYA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.39
-$0.40
-$0.40
-
Expected
-$0.50
-$0.47
-$0.44
-$0.42
-$0.39
Surprise
-10.60%
-17.52%
-8.83%
-5.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tenaya Therapeutics stock?

Tenaya Therapeutics (TNYA) has a market cap of $331M as of June 22, 2024.

What is the P/E ratio for Tenaya Therapeutics stock?

The price to earnings (P/E) ratio for Tenaya Therapeutics (TNYA) stock is 0 as of June 22, 2024.

Does Tenaya Therapeutics stock pay dividends?

No, Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders as of June 22, 2024.

When is the next Tenaya Therapeutics dividend payment date?

Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders.

What is the beta indicator for Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) does not currently have a Beta indicator.

What is the Tenaya Therapeutics stock price target?

The target price for Tenaya Therapeutics (TNYA) stock is $19.29, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Tenaya Therapeutics stock

Buy or sell Tenaya Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing